Novartis receives European Commission approval for self-administration of Xolair® across all indications
The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of […]
TSX News -
Northland Power Announces TSX Approval of Normal Course Issuer Bid
Not for distribution to U.S. newswire services or for dissemination in the United States or its possessions. Any failure to […]
Squire Reports AGM Results; Grants Stock Options
VANCOUVER, British Columbia, Dec. 12, 2018 (GLOBE NEWSWIRE) — Squire Mining Ltd. (CSE:SQR | FWB:9SQ | OTCQB:SQRMF) (“Squire” or the […]
Chvaletice Manganese Project Mineral Resource Update, 2018 Metallurgical Testwork Program Update and Preliminary 2019 Plans
HIGHLIGHTS: Successful 2018 Drilling Program results in updated Mineral Resource Estimate with 98.3% of Resource classified in Measured Category. Drilling […]
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
RADNOR, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing […]
TSX News -
The Keg Royalties Income Fund announces December 2018 cash distribution
VANCOUVER, British Columbia, Dec. 12, 2018 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) today announced […]
NV Gold Files Year End Financial Statements and Announces Board Changes
VANCOUVER, British Columbia, Dec. 12, 2018 (GLOBE NEWSWIRE) — NV Gold Corporation (TSX.V: NVX; OTC Pink: NVGLF) (“NV Gold” or […]
TSX News -
CAPREIT Sells Three Non-Core Quebec City Properties
TORONTO, Dec. 12, 2018 (GLOBE NEWSWIRE) — Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX:CAR.UN) announced today that it […]
TSX News -
High Arctic Announces Appointment of New Director
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS […]
Zynerba Pharmaceuticals Announces Sustained Improvements in Emotional and Behavioral Symptoms of Fragile X Syndrome through 12 Months of Treatment with ZYN002
– Patients Experienced a 77% Improvement in Aberrant Behaviors Associated with Social Avoidance Compared to Baseline after One Year of […]
